ABL Bio Inc
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also … Read more
ABL Bio Inc (298380) - Total Liabilities
Latest total liabilities as of September 2025: ₩52.77 Billion KRW
Based on the latest financial reports, ABL Bio Inc (298380) has total liabilities worth ₩52.77 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ABL Bio Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how ABL Bio Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ABL Bio Inc Competitors by Total Liabilities
The table below lists competitors of ABL Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhengzhou Yutong Bus Co Ltd
SHG:600066
|
China | CN¥18.10 Billion |
|
Endeavor Group Holdings Inc
NYSE:EDR
|
USA | $10.48 Billion |
|
New Residential Investment Corp.
LSE:0K76
|
UK | $43.81 Billion |
|
Wingstop Inc
NASDAQ:WING
|
USA | $1.42 Billion |
|
Giant Network Group Co Ltd
SHE:002558
|
China | CN¥2.98 Billion |
|
Davide Campari Milano SpA
IL:0ROY
|
UK | €4.32 Billion |
|
Middleby Corp
NASDAQ:MIDD
|
USA | $3.54 Billion |
|
Valaris Ltd
NYSE:VAL
|
USA | $2.19 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down ABL Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ABL Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ABL Bio Inc (2016–2024)
The table below shows the annual total liabilities of ABL Bio Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩64.70 Billion | -24.83% |
| 2023-12-31 | ₩86.07 Billion | -25.59% |
| 2022-12-31 | ₩115.67 Billion | +1117.57% |
| 2021-12-31 | ₩9.50 Billion | +2.93% |
| 2020-12-31 | ₩9.23 Billion | -15.28% |
| 2019-12-31 | ₩10.89 Billion | -8.50% |
| 2018-12-31 | ₩11.91 Billion | -88.80% |
| 2017-12-31 | ₩106.32 Billion | +441.66% |
| 2016-12-31 | ₩19.63 Billion | -- |